Non-small cell lung cancer (NSCLC) encompasses squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In the United States in 2015, it is estimated that NSCLC was diagnosed in more than 221,000 individuals and resulted in more than 158,000 deaths. More than 80% of lung cancer patients have NSCLC. The VeriStrat test relies on matrix-assisted laser desorption/deionization time-of-flight (MALDI-TOF) mass spectrometry to analyze pretreatment serum from NSCLC patients who are candidates for EGFR TKI therapy. This test has been developed with the goal of identifying patients most likely to benefit from EGFR TKI therapy. The VeriStrat test is considered a proteomic profiling assay, or a test that identifies specific patterns of protein expression in cells, plasma, or tissue. This report focuses on the use of the VeriStrat test as a prognostic tool and to predict response to EGFR TKIs in NSCLC. 

If you have a Hayes login, click here to view the full report on the Knowledge Center.